December 10, 2020 08:00 AM ESTUpdated 10:10 AM
Deals

Boehringer In­gel­heim buys out next-gen ADC play­er NBE-Ther­a­peu­tics in a deal worth up to $1.4B+

Max Gelman

Senior Editor

Just one day af­ter snag­ging a CD­MO to boost pro­duc­tion of its on­colyt­ic virus and can­cer vac­cine pro­grams, Boehringer In­gel­heim is mak­ing an­oth­er ac­qui­si­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times